Found 5 bookmarks
Newest
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
“If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD”
·x.com·
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
Here is the first randomized trial to show that an antiviral can prevent Long Covid.
Here is the first randomized trial to show that an antiviral can prevent Long Covid.

“Here is the first randomized trial to show that an antiviral can prevent Long Covid.

In the PANORAMIC trial, people randomized to molnupiravir had less risk of Long Covid than people who received no antivirals

My comment in the link below. A short🧵”

·x.com·
Here is the first randomized trial to show that an antiviral can prevent Long Covid.
SARS-CoV-2 antivirals and post-COVID-19 condition
SARS-CoV-2 antivirals and post-COVID-19 condition
“Because SARS-CoV-2 itself is the causative agent of long COVID and because viral persistence is postulated to play a major role in the pathogenesis of the condition, antivirals, which block viral replication, were seen as potential candidates for the prevention and treatment of long COVID.”
Because SARS-CoV-2 itself is the causative agent of long COVID and because viral persistence is postulated to play a major role in the pathogenesis of the condition, antivirals, which block viral replication, were seen as potential candidates for the prevention and treatment of long COVID.
·thelancet.com·
SARS-CoV-2 antivirals and post-COVID-19 condition
"The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID..
"The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID..

Literally living WITH Covid.

The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID

·x.com·
"The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID..
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review

ANTIVIRAL THERAPIES FOR PERSISTENT COVID/LONG COVID 83% SUCCESS 70 of 84 cases with the aggravating factor of immunosuppression

The types of treatment were grouped into: Prolonged Antiviral therapy Combination Antivirals Mixed therapy: Antiviral +Antibody

·onlinelibrary.wiley.com·
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review